Literature DB >> 23248800

Validation of a new questionnaire with generic and disease-specific qualities: the McGill COPD Quality of Life Questionnaire.

Smita Pakhale1, Sharon Wood-Dauphinee, Adriana Spahija, Jean-Paul Collet, Francois Maltais, Sarah Bernard, Marc Baltzan, Michel Rouleau, Jean Bourbeau.   

Abstract

BACKGROUND: A validated health-related quality of life questionnaire in chronic obstructive pulmonary disease (COPD) with advantages of both generic- and disease-specific questionnaires is needed to capture patients' perspectives of severity and impact of the disease. The McGill COPD questionnaire was created to include these advantages in English and French. It assesses three domains: symptoms, physical function and feelings with 29 items (12 from the 36-item Short-Form Health Survey with 17 from the previously developed COPD-specific module).
OBJECTIVE: To evaluate the psychometric properties of this newly developed hybrid questionnaire in subjects with COPD.
METHODS: Data from a multicentre, prospective cohort study involving four hospitals with COPD subjects undergoing pulmonary rehabilitation were used. Patient evaluations included health-related quality of life (the new McGill COPD questionnaire, the St Georges Respiratory Questionnaire and the 36-item Short-Form Health Survey) and pulmonary function tests pre-and postrehabilitation. Reliability, validity and responsiveness were tested.
RESULTS: The study included 246 COPD subjects (111 females) with a mean age of 66 years, 87% ex- and 8% current smokers (mean 61 pack-years) and mean forced expiratory volume in 1 s of 1.12 L (Global initiative for chronic Obstructive Lung Disease stages: 2, 27%; 3, 33%; and 4, 37%). Missing data were <2% and floor and ceiling effects were <5%. Internal consistency (Cronbach's alpha) was 0.68 to 0.82. Test-retest reliability (intracorrelation coefficients) ranged from 0.74 to 0.96 for the subscales, and 0.95 for the total score. Correlation with the St George's Respiratory Questionnaire was moderately high (r=-0.88 [95% CI -0.91 to -0.84]), consistent with the a priori hypothesis for convergent validity. The effect size was 0.33 (pre-postrehabilitation mean score difference = 6), suggesting a small to moderate change.
CONCLUSIONS: The new McGill COPD questionnaire showed high internal consistency, test-retest reliability, validity and moderate responsiveness in COPD subjects.

Entities:  

Mesh:

Year:  2012        PMID: 23248800      PMCID: PMC3603761          DOI: 10.1155/2012/914138

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  36 in total

1.  Optimal number of response categories in rating scales: reliability, validity, discriminating power, and respondent preferences.

Authors:  C C Preston; A M Colman
Journal:  Acta Psychol (Amst)       Date:  2000-03

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

Review 3.  Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ).

Authors:  Holger J Schünemann; Milo Puhan; Roger Goldstein; Roman Jaeschke; Gordon H Guyatt
Journal:  COPD       Date:  2005-03       Impact factor: 2.409

4.  Response and non-response to a quality-of-life question on sexual life: a case study of the simple mean imputation method.

Authors:  Yin Bun Cheung; Rhian Daniel; Gim Yew Ng
Journal:  Qual Life Res       Date:  2006-05-27       Impact factor: 4.147

5.  Are results of the SF-36 health survey and the Nottingham Health Profile similar? A comparison in COPD patients. Quality of Life in COPD Study Group.

Authors:  L Prieto; J Alonso; M Ferrer; J M Antó
Journal:  J Clin Epidemiol       Date:  1997-04       Impact factor: 6.437

6.  A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease.

Authors:  R H Green; S J Singh; J Williams; M D Morgan
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

7.  A measure of quality of life for clinical trials in chronic lung disease.

Authors:  G H Guyatt; L B Berman; M Townsend; S O Pugsley; L W Chambers
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

8.  French-Canadian version of the Chronic Respiratory and St George's Respiratory questionnaires: an assessment of their psychometric properties in patients with chronic obstructive pulmonary disease.

Authors:  Jean Bourbeau; Francois Maltais; Michel Rouleau; Chantal Guímont
Journal:  Can Respir J       Date:  2004-10       Impact factor: 2.409

9.  Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease.

Authors:  T Hajiro; K Nishimura; M Tsukino; A Ikeda; H Koyama; T Izumi
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

Review 10.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

View more
  3 in total

1.  A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales.

Authors:  Michael E Hyland; Ben Whalley; Rupert C Jones; Matthew Masoli
Journal:  Qual Life Res       Date:  2014-09-09       Impact factor: 4.147

Review 2.  A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges.

Authors:  Mario Cazzola; Nicola Alexander Hanania; William MacNee; Katja Rüdell; Claire Hackford; Nihad Tamimi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-04-07

3.  Development and preliminary validation of the chronic obstructive pulmonary disease scale quality of life instruments for chronic diseases-chronic obstructive pulmonary disease based on classical test theory and generalizability theory.

Authors:  Chonghua Wan; Zheng Yang; Zhihuan Zhao; Peng Quan; Bin Wu; Yunbin Yang
Journal:  Chron Respir Dis       Date:  2022 Jan-Dec       Impact factor: 3.115

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.